Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma

Fig. 2

Antibody screening by phage display. a SDS-PAGE of purified wild-type GPC3 (WT) and mutant GPC3 (∆HS) hFc fusion proteins. b Polyclonal phage ELISA to detect the antigen binding activity of three rounds of rescued phages. BSA and frizzled are used as negative antigen controls. c Eluted phage numbers of three rounds of panning. d Monoclonal phage ELISA to analyze GPC3-specific binder. Nine positive clones are marked in dashed boxes (n = 192 clones). BSA and frizzled are used as negative antigen controls. E. Sequence analysis of 9 positive binders identified in d. f SDS-PAGE of purified 32A9 scFv-Fc and 32A9 IgG. R :reducing, NR: non-reducing

Back to article page